---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-040222"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:39:40.231654+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Pharma reports FY2023 net loss of $205M, pipeline advances

## Summary
- Revenue $240.7M vs $243.2M YoY; net loss $205.3M (EPS -$1.92) vs $176.1M (-$1.67).
- Cash and investments $403.6M, down from $482.3M; R&D spend up 19% to $353M.
- Plozasiran (APOC3) showed up to 90% APOC3 reduction in Phase 2 severe hypertriglyceridemia.
- Completed GLP tox for pulmonary candidates ARO-RAGE and ARO-MMP7; planning Phase 2.
- GSK acquired full rights to JNJ-3989 (ARO-HBV) from Janssen; Arrowhead retains no further obligations.

## SEC filing metadata
- accession: 0001628280-23-040222
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/0001628280-23-040222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/arwr-20231129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-040222
- JSON: https://secwatch.observer/filing/0001628280-23-040222.json
- Plain text: https://secwatch.observer/filing/0001628280-23-040222.txt

## Key facts
- Earnings Releases
  ARROWHEAD PHARMACEUTICALS, INC. reported fiscal year ended September 30, 2023 results: revenue $ 240,735, net income $ (205,275), EPS $ (1.92).
  - Period: fiscal year ended September 30, 2023
  - Revenue: $ 240,735
  - Net income: $ (205,275)
  - EPS: $ (1.92)
  - Result: reported results
  source text: PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended September 30, OPERATING SUMMARY 2023 2022 Revenue $ 240,735 $ 243,231 Operating Expenses: Research and development 353,188 297,307 General and administrative expenses 92,549 124,431 Total Operating Expenses 445,737 421,738 Operating loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/0001628280-23-040222-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.